氟达拉滨联合环磷酰胺治疗慢性淋巴细胞白血病的临床研究

Clinical study of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

目的研究氟达拉滨联合环磷酰胺(FC方案)治疗慢性淋巴细胞白血病的近期疗效和不良反应。方法回顾性对照分析FC方案和环磷酰胺联合长春新碱、阿霉素、强的松(CHOP方案)治疗成人慢性淋巴细胞白血病(CLL)的疗效及不良反应。结果FC方案组与CHOP方案组完全缓解率分别是33.3%和14.3%(P=0.175),总有效率分别为86.7%和52.4%(P=0.031)。两组方案对WBC、PLT的抑制程度以及不良反应方面,两组方案差异无统计学意义。结论FC方案诱导治疗成人CLL的完全缓解率和总有效率均高于CHOP方案.其中总有效率两组方案差异有统计学意义;两组方案不良反应差异无统计学意义,FC方案可以作为成人CLL患者一线化疗方案。

Objective To assess the efficacy of combination therapy with fludarabine and cyclophosphamide in treating patients of chronic lymphocytic leukemia （CLL）. Methods Retrospective studying the efficacy and toxicity of CLL patients who treated with FC regimen and cyclophosphamide, vincristine, prednisone plus doxorubicin （CHOP regimen）. Results In FC regimen and CHOP regimen, the complete remission （CR）rates were 33.3% and 14.3 % （P = 0. 175）, respectively, the overall remission rates were 86.7% and 52.4% （P=0. 031） ,respectively. No significant differences were found in WBC,PLT depression or the incidence and severity of side effects between two regimens. Conclusion Compared to ChOP,FC induced higher overall remission rates （P= 0. 031）,including higher complete remission rates （P=0. 175）, but no significant difference is found in side effects between two regimens. FC regimen is recommended as the first line therapy in the treatment of CLL patients.